EE649 Cost Per Responder of Bimekizumab Against Il-17A, IL-12/23 and IL-23 Inhibitors in the Treatment of Psoriatic Arthritis in Sweden

Abstract

Authors

N. Lyris K. Geale M. Aldvén A. Engström D. Willems

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×